API
Naproxen
KDMF APIs
Naproxen
Korean name | 나프록센 |
|---|---|
Category | Central nervous system |
CAS No. | 22204-53-1 |
KDMF registration No. | 20130821-143-I-336-08(3) |
Manufacturer | Divi’s Laboratories Limited. |
Specification | USP |
Product information
IUPAC Name | (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid |
|---|---|
Synonyms | (+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid (+)-(S)-Naproxen (+)-2-(6-Methoxy-2-naphthyl)propionic acid (+)-2-(Methoxy-2-naphthyl)-propionic acid (+)-2-(Methoxy-2-naphthyl)-propionsäure (+)-Naproxen (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid (S)-(+)-Naproxen (S)-2-(6-Methoxy-2-naphthyl)propanoic acid (S)-2-(6-Methoxy-2-naphthyl)propionic acid (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid (S)-Naproxen |
Description | Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given it's overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers. |
Certificate of Analysis | If you need more information, please contact us. |
If you need additional documents such as specifications or certificates of analysis, please request them together with your inquiry. Our team will review and reply. (02-579-1056 · ace@acebiopharm.com)